Last update : 07/22/2015 | Version : 2 | ID : 5419
General | |
Identification | |
Detailed name | Patients who did not relapse after stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia |
Sign or acronym | Les STIMS |
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL n°1245229 |
General Aspects | |
Medical area |
Immunology |
Keywords | Tyrosine kinase inhibitors, stopping treatment, complete molecular remission, relapse. |
Scientific investigator(s) (Contact) | |
Name of the director | Mahon |
Surname | François-Xavier |
Address | Université Bordeaux Ségalen, 146 rue Léo Saignat, 33076 BORDEAUX |
Phone | + 33 (0)5 57 57 15 24 |
Francois-Xavier.Mahon@u-bordeaux2.fr | |
Unit | Hématopoïèse Leucémique et Cible thérapeutiques |
Organization | Université Bordeaux |
Name of the director | Bouvier |
Surname | Séverine |
Collaborations | |
Funding | |
Funding status |
Mixed |
Details | PHRC 2006 |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | Université Bordeaux Ségalen |
Organisation status |
Public |
Additional contact | |
Main features | |
Type of database | |
Type of database |
Study databases |
Study databases (details) |
Longitudinal study (except cohorts) |
Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
Database recruitment is is made on the basis of: |
Medication(s) taken |
Database recruitment is carried out as part of an interventional study |
No |
Additional information regarding sample selection. | Subjects meeting inclusion and exclusion criteria must sign a consent |
Database objective | |
Main objective | To monitor patients who discontinued tyrosine kinase inhibitors for at least two years in order to determine their molecular status and collate potential late molecular relapses. |
Inclusion criteria | Men or women aged 18 years and older Chronic myeloid leukaemia in chronic or accelerated phase under treatment with Imatinib for at least 3 years Complete molecular remission under treatment with Imatinib for at least 2 years For the women old enough to procreate, a method of effective contraception Subjects covered by or affiliated with a social security scheme Negative HIV serology and absence of chronic hepatitis B or C Free and informed consent in writing Molecular monitoring as recommended by European "LeukemiaNet" |
Population type | |
Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) |
Population covered |
Sick population |
Gender |
Male Woman |
Geography area |
National |
Detail of the geography area | France |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 2010 |
Size of the database | |
Size of the database (number of individuals) |
< 500 individuals |
Details of the number of individuals | 100 |
Data | |
Database activity |
Current data collection |
Type of data collected |
Clinical data Biological data |
Clinical data (detail) |
Medical registration |
Biological data (detail) | BCR-ABL transcript level |
Presence of a biobank |
No |
Health parameters studied |
Health event/morbidity Health event/mortality Health care consumption and services |
Care consumption (detail) |
Medicines consumption |
Procedures | |
Data collection method | After the accuracy of the data is verified, they are collected by mail or directly on site by the person in charge of verification every 3-6 months. The same person enters the data in an Access database, which is then transferred to a biostatistician. This is done centrally. |
Participant monitoring |
Yes |
Details on monitoring of participants | The BCR-ABL transcript level is measured by quantitative RT-PCR in molecular biology laboratories every 3 months following a blood sample from the patient. |
Links to administrative sources |
No |
Promotion and access | |
Promotion | |
Link to the document | http://tinyurl.com/Pubmed-STIMS |
Description | List of publications in Pubmed |
Access | |
Terms of data access (charter for data provision, format of data, availability delay) | Publications Data are accesible by other researchers by request if required (via secure Excel files graphics, etc.) |
Access to aggregated data |
Access on specific project only |
Access to individual data |
Access on specific project only |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05